Early trial for Tough-to-Treat blood cancer halted before starting
NCT ID NCT04392648
Summary
This study aimed to test the safety and find the right dose of an experimental drug called TAK-573 when given with other standard medications to people with multiple myeloma that has returned or stopped responding to prior treatments. The trial was designed to enroll about 135 participants but was withdrawn before any patients were enrolled. The main goals were to check for side effects and see if the drug combination could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.